An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Inrebic

Chemical Namefedratinib
Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyImpact
Approval Year2019

Indication

  • Inrebic is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inrebic (fedratinib) Prescribing Information 2019Celgene
Document TitleYearSource
Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis2015JAMA Oncology